Announcement on Convening the 2025 Annual Performance Briefing
Filed with SSE · · 3 pages · Chinese
Earlier from InnoCare Pharma
- InnoCare Announces First Healthy Volunteer Dosed in Clinical Trial of Novel VAV1 Degrader ICP-538 in China
- InnoCare’s next-generation TRKi Zurletrectinib Receives Priority Review for the Treatment of Pediatric Patients with Solid Tumors in China
- InnoCare Announces Key Developments of Critical Clinical Studies
- InnoCare Announces First Patient Dosed in the Phase II/III Clinical Trial of Novel TYK2 Inhibitor Soficitinib for Chronic Spontaneous Urticaria in China
- InnoCare Announces IND Approval to Initiate Clinical Trial of VAV1 Degrader ICP-538 in China
Later from InnoCare Pharma
- InnoCare Releases 2025 Results and Business Highlights, Achieving First Annual Profit
- Announcement on Convening the Q1 2026 Performance Briefing
- Preclinical Data of Novel B7-H3 ADC ICP-B794 Unveiled at 2026 AACR, Demonstrating Superior Anti-Tumor Activity and Safety
- InnoCare Releases 2026 Q1 Results: Strong Revenue Growth and Sustained Profitability
- Notice on Convening the 2026 Annual General Meeting
Follow InnoCare Pharma into a list and get an email when it puts out news.
Follow InnoCare Pharma